APOB and acute coronary syndrome: The ODYSSEY OUTCOMES study tested the benefit of alirocumab in patients with previous acute coronary syndrome within the past year and with LDL-C values of at least 70 mg per deciliter, a non-HDL cholesterol level of at least 100 mg per deciliter, or a level of Apolipoprotein B (Apo B) of at least 80 mg per deciliter treated at the maximum tolerated dose of a statin [24].